Recent studies into retatrutide, a dual agonist for GLP-1 and GIP receptors, are showing significant outcomes in treating obesity and type second-type disease. Animal data suggest a distinct mechanism contributing to https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/